Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RAVULIZUMAB vs REGORAFENIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RAVULIZUMAB vs REGORAFENIB: Safety Overview

Metric RAVULIZUMAB REGORAFENIB
Total FAERS Reports 118 9,441
Deaths Reported 11 1,869
Death Rate 9.3% 19.8%
Hospitalizations 89 3,363
Average Patient Age 48.4 yrs 62.2 yrs
% Female Patients 56.3% 39.9%
FDA Approval Date N/A Jan 13, 2025
Manufacturer Alexion Pharmaceuticals Inc. Bayer HealthCare Pharmaceuticals Inc.
Route INTRAVENOUS ORAL
Marketing Status N/A Prescription